Share on StockTwits

Trimel Pharmaceuticals (TSE:TRL) posted its quarterly earnings results on Friday. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.04) by $0.01, Analyst Ratings Net reports.

Trimel Pharmaceuticals (TSE:TRL) opened at 0.60 on Friday. Trimel Pharmaceuticals has a 52-week low of $0.335 and a 52-week high of $0.93. The stock has a 50-day moving average of $0.67 and a 200-day moving average of $0.6. The company’s market cap is $97.9 million.

Several analysts have recently commented on the stock. Analysts at Paradigm Capital cut their price target on shares of Trimel Pharmaceuticals from C$2.25 to C$2.00 in a research note on Monday, July 21st. They now have a “buy” rating on the stock. Analysts at RBC Capital reiterated an “outperform” rating on shares of Trimel Pharmaceuticals in a research note on Monday, May 12th. They now have a C$1.00 price target on the stock, down previously from C$1.50.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.